Medication info
Innoen Metformin Extended-Release Tablets (Metformin Hydrochloride)

Innoen Metformin Extended-Release Tablets (Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
HK inno.N Co., Ltd.
Appearance
White rectangular tablet
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Active

MFDS item code 201401518 · Approved 2014.03.31

Summary

Main use
Treatment of type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose should be determined individually based on drug efficacy and tolerability and should not exceed the recommended maximum daily dose. The usual initial dose is one metformin hydrochloride extended-release tablet 500mg once daily with the evening meal. Measure blood glucose levels after one week and adjust the dose. Gastrointestinal adverse reactions may improve with gradual dose increases. The maximum dose is 2000mg per day. When increasing the dose, increase by 500mg each week, up to a maximum of 2000mg daily with the evening meal. If glycemic control is not achieved with a maximum once-daily dose of 2000mg, consider administering 1000mg twice daily; both doses should be taken with meals. For patients already being treated with metformin tablets, the initial dose of this formulation is the same as the daily dose of immediate-release metformin tablets. Switching to this formulation is not recommended for patients taking more than 2000mg of immediate-release metformin tablets per day. During initiation and dose adjustment, measure fasting blood glucose to assess the response to treatment with this drug and determine the minimum effective dose. Measure blood glycated hemoglobin approximately every 3 months. The goal of treatment with this drug, whether used as monotherapy or in combination with a sulfonylurea or insulin, is to reduce fasting blood glucose and blood glycated hemoglobin levels to normal or near-normal levels using the minimum effective dose. Patients with renal impairment This drug may be used in patients with moderate stage 3a renal impairment (creatinine clearance [CrCl] 45≤~ <60ml/min or glomerular filtration rate (GFR) 45≤~ <60 mL/min/1.73 m2) who have no other conditions that may increase the risk of lactic acidosis, with the following dose adjustments. The starting dose is 500mg or 750mg once daily. The maximum daily dose is 1000mg. Renal function should be monitored closely every 3- 6 months. If creatinine clearance or glomerular filtration rate falls below 45ml/min or 45ml/min/1.73m2, respectively, this drug should be discontinued immediately.

Ingredients

Manufacturer
HK inno.N Co., Ltd.

Efficacy & effects

Treatment of type 2 diabetes mellitus

  • Type 2 diabetes with insufficient blood sugar control
View approved original text

This medication is used for the treatment of adult patients with type 2 diabetes whose blood sugar control is insufficient with diet and exercise alone. It is especially effective in overweight diabetic patients and can be used alone or in combination with other oral hypoglycemic agents or insulin. This helps improve blood sugar levels and assists in diabetes management.

How to take

Adult dose

The dose should be determined individually based on drug efficacy and tolerability and should not exceed the recommended maximum daily dose. The usual initial dose is one metformin hydrochloride extended-release tablet 500mg once daily with the evening meal. Measure blood glucose levels after one week and adjust the dose. Gastrointestinal adverse reactions may improve with gradual dose increases. The maximum dose is 2000mg per day. When increasing the dose, increase by 500mg each week, up to a maximum of 2000mg daily with the evening meal. If glycemic control is not achieved with a maximum once-daily dose of 2000mg, consider administering 1000mg twice daily; both doses should be taken with meals. For patients already being treated with metformin tablets, the initial dose of this formulation is the same as the daily dose of immediate-release metformin tablets. Switching to this formulation is not recommended for patients taking more than 2000mg of immediate-release metformin tablets per day. During initiation and dose adjustment, measure fasting blood glucose to assess the response to treatment with this drug and determine the minimum effective dose. Measure blood glycated hemoglobin approximately every 3 months. The goal of treatment with this drug, whether used as monotherapy or in combination with a sulfonylurea or insulin, is to reduce fasting blood glucose and blood glycated hemoglobin levels to normal or near-normal levels using the minimum effective dose. Patients with renal impairment This drug may be used in patients with moderate stage 3a renal impairment (creatinine clearance [CrCl] 45≤~ <60ml/min or glomerular filtration rate (GFR) 45≤~ <60 mL/min/1.73 m2) who have no other conditions that may increase the risk of lactic acidosis, with the following dose adjustments. The starting dose is 500mg or 750mg once daily. The maximum daily dose is 1000mg. Renal function should be monitored closely every 3- 6 months. If creatinine clearance or glomerular filtration rate falls below 45ml/min or 45ml/min/1.73m2, respectively, this drug should be discontinued immediately.

Precautions

This medication can rarely cause a condition called lactic acidosis, which is a dangerous complication that can be life-threatening. Care should be taken when used with other diabetes medications, as hypoglycemia may occur. This medication should not be used in patients with moderate to severe kidney impairment, dehydration, serious infections, or heart problems. Administration should be temporarily suspended before and after tests using iodinated contrast media, resuming only after kidney function is confirmed to be normal. Patients with allergies to this medication or similar drugs should not take it. It is not suitable for patients with type 1 diabetes or diabetic ketoacidosis. This medication should also be temporarily discontinued in cases of severe infection, major injury, or before and after surgery, and can be resumed after the patient's condition has recovered. Caution is required in patients with poor nutritional status, decreased liver function, or excessive alcohol consumption. Pregnant women with placental function issues or at risk for preeclampsia are advised against using this medication. Patients with irregular or insufficient food intake, those engaging in rigorous exercise, or those at risk of drug interactions should be treated cautiously. While taking this medication, kidney function should be regularly monitored to prevent the buildup of the drug in the body, leading to dangerous conditions. Gastrointestinal symptoms may often occur during initial treatment but usually improve over time. In case of severe diarrhea or vomiting, the risk of dehydration may necessitate temporary discontinuation of the medication. While this medication rarely causes hypoglycemia on its own, patients should be cautious about hypoglycemia symptoms when used with other hypoglycemic agents. Alcohol consumption can increase risks when taking this medication, so excessive drinking should be avoided. If blood sugar control is needed during pregnancy, this medication may be used at the discretion of a physician, but careful monitoring of fetal growth is necessary. Breastfeeding mothers must consider whether to continue nursing or to discontinue medication, as this drug is excreted in breast milk. It is not recommended for children as safety and efficacy have not been established. Elderly patients are at higher risk of decreased kidney function, requiring careful dose adjustments and regular kidney function monitoring. In the case of overdose, inform medical personnel immediately due to the risk of lactic acidosis, and treatment may include dialysis if necessary. This medication should be swallowed whole without chewing or crushing, and it is normal for the tablet coating to appear in the stool. Regular blood sugar and kidney function tests should be performed to confirm therapeutic effectiveness and safety during treatment.

Side effects

  • severe lactic acidosis
  • severe hypoglycemia
  • vitamin B12 deficiency
  • taste impairment
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • loss of appetite
  • erythema
Show 3 more
  • pruritus
  • urticaria
  • rash

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it should be stored in a tightly sealed container. It is best to maintain room temperature between 1-degree Celsius and 30-degree Celsius for optimal efficacy.

Appearance and packaging

Appearance

White rectangular tablet

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.